Results 351 to 360 of about 13,097,347 (378)
Some of the next articles are maybe not open access.
EXPERIENCE WITH AMPHOTERICIN B
Annals of the New York Academy of Sciences, 1960Harry E. Dascomb, John H. Seabury
openaire +3 more sources
[Amphotericin B: the end of an era].
Nederlands tijdschrift voor geneeskunde, 2004For 45 years, amphotericin B has been the drug of choice for the treatment of invasive mycoses. Because of its severe toxicity, lipid-associated formulations of amphotericin B have been developed. Although comparative trials are scarce, there appears to be no convincing advantage of these new formulations in terms of efficacy.
Oude Lashof, A.M.L., Kullberg, B.J.
openaire +2 more sources
Retrobulbar Injection of Amphotericin B for Orbital Mucormycosis.
Ophthalmic Plastic and Reconstructive Surgery, 2017Kristin E Hirabayashi +5 more
semanticscholar +1 more source
Efficacy and safety of amphotericin B lipid‐based formulations—A systematic review and meta‐analysis
Mycoses (Berlin), 2017L. Steimbach +7 more
semanticscholar +1 more source
Intraorbital Irrigation of Amphotericin B in the Treatment of Rhino-Orbital Mucormycosis.
Ophthalmic Plastic and Reconstructive Surgery, 2017Z. Joos, B. Patel
semanticscholar +1 more source
Topical Amphotericin B solid lipid nanoparticles: Design and development.
Colloids and Surfaces B: Biointerfaces, 2016Dhruv Butani, Chetan Yewale, A. Misra
semanticscholar +1 more source